AMENDMENTS TO THE CLAIMS

1-20. (canceled)

- 21. (Currently amended): A method for treating and/or preventing inhibiting platelet membrane receptor protein gpHb/IIIa glycoprotein (gp)IIb/IIIa-associated disorders activation in a mammal, including human, comprising administering to the mammal an effective amount of adenosine that is effective in inhibiting the activation of platelet membrane receptor protein gpHb/IIIa.
- 22. (previously presented): The method of claim 21, wherein the activation of platelet membrane receptor protein gpIIb/IIIa induces platelet aggregation or thrombosis.
- 23. (previously presented): The method of claim 21, wherein the platelet membrane receptor protein gpIIb/IIIa-associated disorder is induces a thromboembolic disorder-selected from the group consisting of atheroselerosis, arterioselerosis, acute myocardial infarction, angina, transient ischemic attack, stroke, peripheral vascular disease, arterial thrombosis, preeclampsia, embolism and carotid endarterectomy.

24-25 (Canceled)

- 26. (Currently amended): A pharmaceutical composition for treating and/or preventing inhibiting the activation of platelet membrane receptor protein gpIIb/IIIa-associated disorders activation in a mammal, including human, comprising an effective amount of adenosine that is effective in inhibiting the activation of platelet membrane receptor protein gpIIb/IIIa and a pharmaceutically acceptable carrier or diluent.
- 27. (previously presented): The pharmaceutical composition of claim 26, wherein the activation of platelet membrane receptor protein gpIIb/IIIa induces platelet aggregation or thrombosis.
- 28. (Currently amended): The pharmaceutical composition of claim 26, wherein the platelet membrane receptor protein gpIIb/IIIa-associated disorder is induces a thromboembolic

disorder-selected from the group consisting of atheroselerosis, arterioselerosis, acute myocardial infarction, angina, transient ischemic attack, stroke, peripheral vascular disease, arterial thrombosis, preeclampsia, embolism and carotid endarterectomy.

29-33 (Canceled):

- 34. (New) The method according to claim 23, wherein said thromboembolic disorder is selected from the group consisting of atherosclerosis, arteriosclerosis, acute myocardial infarction, angina, transient ischemic attack, stroke, peripheral vascular disease, arterial thrombosis, preeclampsia, embolism and carotid endarterectomy.
- 35. (New) The method according to claim 28, wherein said thromboembolic disorder is selected from the group consisting of atherosclerosis, arteriosclerosis, acute myocardial infarction, angina, transient ischemic attack, stroke, peripheral vascular disease, arterial thrombosis, preeclampsia, embolism and carotid endarterectomy